ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2057

Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia Using a Dual-Energy CT Scan

Penny Wang1, Stacy Smith2, Rajesh Garg3, Fengxin Lu1, Alyssa Wohlfahrt1, Anarosa Campos1, Kathleen Vanni4, Zhi Yu5, Daniel H. Solomon1 and Seoyoung C. Kim1, 1Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 2Radiology, Division of Musculoskeletal Imaging and Intervention, Brigham and Women's Hospital, Boston, MA, 3Division of Endocrinology, Diabetes & Hypertension, Brigham and Women's Hospital, Boston, MA, 4Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, MA, 5Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: gout, hyperuricemia and uric acid, Imaging

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 7, 2017

Title: Metabolic and Crystal Arthropathies Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Serum uric acid (sUA) is a useful indicator of the risk of developing gout.  However, most patients with elevated sUA levels do not have gout. Dual-energy computed tomography (DECT) scan is a relatively sensitive and specific imaging tool used to measure and visualize urate deposits in the joints. Prior research shows presence of subclinical urate deposits in nearly one-quarter of patients with severe hyperuricemia (i.e., sUA >9 mg/dl) without gout.  We conducted a cross-sectional study to identify urate deposits using DECT and examine whether an association exists between sUA levels and total volume of urate deposits in patients with asymptomatic hyperuricemia.

Methods: We recruited adults aged ≥40 years with sUA levels ≥6.5 mg/dl and metabolic syndrome according to the National Cholesterol Education Program–Adult Treatment Panel III criteria. We excluded patients with gout, end-stage renal disease, renal replacement therapy, active malignancy, and use of xanthine oxidase inhibitors, colchicine or probenecid. All patients underwent a measurement of sUA level and DECT scan of a foot.  A fellowship trained MSK radiologist processed and reviewed the DECT images and determined total volume of urate deposits. We used logistic regression to assess the association between sUA and presence of urate deposits and linear regression to examine the association between sUA and total volume of urate deposits.  

Results: A total of 46 subjects participated in this study.  The mean age was 62 (±8) years, 41% were male and mean sUA level was 7.8 (±1.0) mg/dl.  Seven of 46 (15%) patients had urate deposits in the feet. The mean total volume of urate deposits was 0.13 (±0.14) cm3. On univariable analysis, age had significant association with presence of urate deposits but sUA, male sex, body mass index, presence of diabetes, and renal function did not (Table). sUA had a modest linear association (β coefficient=0.11, p=0.09), albeit statistically not significant, with total volume of urate deposits (Figure).

Conclusion: In this cross-sectional study, 15% of patients with elevated sUA but no known gout had urate deposits in the foot DECT scan. There were no clear patient factors other than older age associated with presence of urate deposits on DECT scans.  While the clinical significance of these urate deposits is unclear, it is possible that these patients may develop gouty arthritis or they may have “resistance” to reacting against urate depositis.  Further research on why certain patients with hyperuricemia develop gout may present important clues to gout prevention.


Disclosure: P. Wang, None; S. Smith, None; R. Garg, None; F. Lu, None; A. Wohlfahrt, None; A. Campos, None; K. Vanni, None; Z. Yu, None; D. H. Solomon, AstraZeneca, 2,Bristol-Myers Squibb, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2; S. C. Kim, AstraZeneca, 2,Pfizer Inc, 2,Roche Pharmaceuticals, 2,Bristol-Myers Squibb, 2,Merck Human Health, 2.

To cite this abstract in AMA style:

Wang P, Smith S, Garg R, Lu F, Wohlfahrt A, Campos A, Vanni K, Yu Z, Solomon DH, Kim SC. Identification of Urate Deposits in Patients with Asymptomatic Hyperuricemia Using a Dual-Energy CT Scan [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/identification-of-urate-deposits-in-patients-with-asymptomatic-hyperuricemia-using-a-dual-energy-ct-scan/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/identification-of-urate-deposits-in-patients-with-asymptomatic-hyperuricemia-using-a-dual-energy-ct-scan/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology